No Data
No Data
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $180
Analysts Conflicted on These Healthcare Names: Spruce Biosciences (OtherSPRB), Cigna (CI) and Axsome Therapeutics (AXSM)
Axsome Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Axsome Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $180 From $200
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $153
Baird Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $162